Geron (GERN) Competitors

Geron logo
$1.00 +0.06 (+6.17%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$1.00 +0.00 (+0.50%)
As of 11/17/2026 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GERN vs. ALKS, NAMS, PVLA, CLDX, and SEPN

Should you buy Geron stock or one of its competitors? Geron's main competitors and comparable companies include Alkermes (ALKS), NewAmsterdam Pharma (NAMS), Palvella Therapeutics (PVLA), Celldex Therapeutics (CLDX), and Septerna (SEPN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Geron compare to Alkermes?

Geron (NASDAQ:GERN) and Alkermes (NASDAQ:ALKS) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

Geron presently has a consensus price target of $3.75, indicating a potential upside of 275.00%. Alkermes has a consensus price target of $55.73, indicating a potential upside of 22.63%. Given Geron's higher possible upside, equities analysts plainly believe Geron is more favorable than Alkermes.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Geron
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.33
Alkermes
1 Sell rating(s)
5 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.65

Geron has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market. Comparatively, Alkermes has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market.

Alkermes has a net margin of -0.02% compared to Geron's net margin of -23.04%. Alkermes' return on equity of 0.40% beat Geron's return on equity.

Company Net Margins Return on Equity Return on Assets
Geron-23.04% -16.29% -6.82%
Alkermes -0.02%0.40%0.19%

73.7% of Geron shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 1.7% of Geron shares are owned by insiders. Comparatively, 4.6% of Alkermes shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Alkermes had 12 more articles in the media than Geron. MarketBeat recorded 17 mentions for Alkermes and 5 mentions for Geron. Geron's average media sentiment score of 0.86 beat Alkermes' score of 0.85 indicating that Geron is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Geron
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Alkermes
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Positive

Alkermes has higher revenue and earnings than Geron. Alkermes is trading at a lower price-to-earnings ratio than Geron, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Geron$183.88M3.50-$83.50M-$0.08N/A
Alkermes$1.48B5.17$241.66M-$0.02N/A

Summary

Alkermes beats Geron on 14 of the 17 factors compared between the two stocks.

How does Geron compare to NewAmsterdam Pharma?

NewAmsterdam Pharma (NASDAQ:NAMS) and Geron (NASDAQ:GERN) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

NewAmsterdam Pharma has a beta of 0.15, meaning that its stock price is 85% less volatile than the broader market. Comparatively, Geron has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market.

In the previous week, NewAmsterdam Pharma had 3 more articles in the media than Geron. MarketBeat recorded 8 mentions for NewAmsterdam Pharma and 5 mentions for Geron. Geron's average media sentiment score of 0.86 beat NewAmsterdam Pharma's score of 0.32 indicating that Geron is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NewAmsterdam Pharma
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Geron
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

NewAmsterdam Pharma currently has a consensus price target of $49.82, suggesting a potential upside of 156.93%. Geron has a consensus price target of $3.75, suggesting a potential upside of 275.00%. Given Geron's higher possible upside, analysts clearly believe Geron is more favorable than NewAmsterdam Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NewAmsterdam Pharma
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.83
Geron
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.33

89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 73.7% of Geron shares are held by institutional investors. 12.7% of NewAmsterdam Pharma shares are held by insiders. Comparatively, 1.7% of Geron shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Geron has a net margin of -23.04% compared to NewAmsterdam Pharma's net margin of -789.95%. Geron's return on equity of -16.29% beat NewAmsterdam Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
NewAmsterdam Pharma-789.95% -31.39% -28.32%
Geron -23.04%-16.29%-6.82%

Geron has higher revenue and earnings than NewAmsterdam Pharma. Geron is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NewAmsterdam Pharma$22.50M103.35-$203.82M-$1.69N/A
Geron$183.88M3.50-$83.50M-$0.08N/A

Summary

Geron beats NewAmsterdam Pharma on 9 of the 17 factors compared between the two stocks.

How does Geron compare to Palvella Therapeutics?

Geron (NASDAQ:GERN) and Palvella Therapeutics (NASDAQ:PVLA) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

Geron currently has a consensus target price of $3.75, suggesting a potential upside of 275.00%. Palvella Therapeutics has a consensus target price of $214.86, suggesting a potential upside of 48.84%. Given Geron's higher possible upside, equities research analysts clearly believe Geron is more favorable than Palvella Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Geron
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.33
Palvella Therapeutics
1 Sell rating(s)
0 Hold rating(s)
13 Buy rating(s)
2 Strong Buy rating(s)
3.00

Geron has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.21, indicating that its share price is 121% less volatile than the broader market.

In the previous week, Palvella Therapeutics had 5 more articles in the media than Geron. MarketBeat recorded 10 mentions for Palvella Therapeutics and 5 mentions for Geron. Palvella Therapeutics' average media sentiment score of 0.99 beat Geron's score of 0.86 indicating that Palvella Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Geron
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Palvella Therapeutics
4 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Palvella Therapeutics has lower revenue, but higher earnings than Geron. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Geron, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Geron$183.88M3.50-$83.50M-$0.08N/A
Palvella Therapeutics$42.81M49.30-$41.72M-$5.50N/A

73.7% of Geron shares are owned by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are owned by institutional investors. 1.7% of Geron shares are owned by company insiders. Comparatively, 17.2% of Palvella Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Palvella Therapeutics has a net margin of 0.00% compared to Geron's net margin of -23.04%. Geron's return on equity of -16.29% beat Palvella Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Geron-23.04% -16.29% -6.82%
Palvella Therapeutics N/A -44.44%-36.75%

Summary

Palvella Therapeutics beats Geron on 9 of the 16 factors compared between the two stocks.

How does Geron compare to Celldex Therapeutics?

Geron (NASDAQ:GERN) and Celldex Therapeutics (NASDAQ:CLDX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Geron has higher revenue and earnings than Celldex Therapeutics. Geron is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Geron$183.88M3.50-$83.50M-$0.08N/A
Celldex Therapeutics$1.54M1,430.40-$258.76M-$4.30N/A

Geron presently has a consensus price target of $3.75, indicating a potential upside of 275.00%. Celldex Therapeutics has a consensus price target of $64.08, indicating a potential upside of 128.54%. Given Geron's higher probable upside, equities research analysts clearly believe Geron is more favorable than Celldex Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Geron
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.33
Celldex Therapeutics
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.77

Celldex Therapeutics has a net margin of 0.00% compared to Geron's net margin of -23.04%. Geron's return on equity of -16.29% beat Celldex Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Geron-23.04% -16.29% -6.82%
Celldex Therapeutics N/A -52.66%-47.58%

73.7% of Geron shares are owned by institutional investors. 1.7% of Geron shares are owned by insiders. Comparatively, 5.2% of Celldex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Geron had 2 more articles in the media than Celldex Therapeutics. MarketBeat recorded 5 mentions for Geron and 3 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 0.93 beat Geron's score of 0.86 indicating that Celldex Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Geron
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Celldex Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Geron has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market.

Summary

Geron beats Celldex Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Geron compare to Septerna?

Septerna (NASDAQ:SEPN) and Geron (NASDAQ:GERN) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

73.7% of Geron shares are owned by institutional investors. 5.8% of Septerna shares are owned by insiders. Comparatively, 1.7% of Geron shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Septerna has a beta of 2.2, indicating that its stock price is 120% more volatile than the broader market. Comparatively, Geron has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market.

Geron has a net margin of -23.04% compared to Septerna's net margin of -61.29%. Septerna's return on equity of -14.98% beat Geron's return on equity.

Company Net Margins Return on Equity Return on Assets
Septerna-61.29% -14.98% -10.03%
Geron -23.04%-16.29%-6.82%

In the previous week, Septerna had 17 more articles in the media than Geron. MarketBeat recorded 22 mentions for Septerna and 5 mentions for Geron. Geron's average media sentiment score of 0.86 beat Septerna's score of 0.32 indicating that Geron is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Septerna
4 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Geron
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Septerna has higher earnings, but lower revenue than Geron. Septerna is trading at a lower price-to-earnings ratio than Geron, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Septerna$45.95M41.41-$48.88M-$1.29N/A
Geron$183.88M3.50-$83.50M-$0.08N/A

Septerna presently has a consensus price target of $56.44, indicating a potential upside of 41.04%. Geron has a consensus price target of $3.75, indicating a potential upside of 275.00%. Given Geron's higher probable upside, analysts plainly believe Geron is more favorable than Septerna.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Septerna
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.82
Geron
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.33

Summary

Septerna beats Geron on 9 of the 17 factors compared between the two stocks.

Get Geron News Delivered to You Automatically

Sign up to receive the latest news and ratings for GERN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GERN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GERN vs. The Competition

MetricGeronBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$606.81M$4.06B$7.83B$11.74B
Dividend YieldN/A3.63%2.47%4.47%
P/E Ratio-12.5026.0433.0226.92
Price / Sales3.5016.068.565.70
Price / CashN/A22.9521.0121.90
Price / Book2.864.184.463.72
Net Income-$83.50M-$24.15M$3.52B$393.10M
7 Day Performance-1.96%-7.80%-5.94%-5.76%
1 Month Performance-14.53%-5.98%-4.59%-7.14%
1 Year Performance-9.91%-8.10%-1.94%-7.46%

Geron Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GERN
Geron
3.9281 of 5 stars
$1.00
+6.2%
$3.75
+275.0%
-11.5%$606.81M$183.88MN/A258
ALKS
Alkermes
2.7408 of 5 stars
$46.98
-1.9%
$55.73
+18.6%
+55.0%$8.05B$1.48B1,596.332,050
NAMS
NewAmsterdam Pharma
3.3622 of 5 stars
$19.97
-3.6%
$49.82
+149.5%
-49.7%$2.48B$22.50MN/A100
PVLA
Palvella Therapeutics
2.5933 of 5 stars
$153.18
-6.6%
$213.85
+39.6%
+76.8%$2.40B$42.81MN/A29
CLDX
Celldex Therapeutics
1.8844 of 5 stars
$28.53
-5.4%
$64.08
+124.6%
+7.8%$2.37B$1.54MN/A198

Related Companies and Tools


This page (NASDAQ:GERN) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners